Akeylink Pharmaceuticals
- Biotech or pharma, therapeutic R&D
6 proprietary small molecule assets in clinical development are avaialable for partnering including:
GST-HG171, a best-in-class 3CL inhibitor (approved for treating COVID-19 infection in China since 2023);
GST-HG141, a novel capsid modulator (CAM), recently completed Ph2 trial with positive outcome for treating HBV infection and is Ph3 ready;
GST-HG131, an orally bioavailable, novel HBV cell surface antigen inhibitor, which completed Ph2 trial with positive results;
GST-HG151, a novel ASK-1 inhibitor for treatment of fibrosis, currently in Ph1 trial.
Address
ShanghaiShanghai
China
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}